NCT00824746

Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)

Retreatment of Gefitinib in the Patients With Non-small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Chonnam National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A single arm, open label, prospective, phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous gefitinib failure. Primary endpoint * to assess Disease Control Rate (Remission + Stable disease) Secondary endpoints * to assess the progression free survival

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	Gefitinib retreatment	phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.

Timeline

• Start date: 2009-01-01
• Primary completion: 2011-06-01
• Completion: 2011-12-01
• First posted: 2009-01-19
• Last updated: 2013-02-26
• Results posted: 2013-02-26

Locations

1 site across 1 country: South Korea